Literature DB >> 821784

Behavioral procedures for evaluating the relative abuse potential of CNS drugs in primates.

J V Brady, R R Griffiths.   

Abstract

Laboratory animal drug self-administration procedures for evaluating pharmacological abuse potential have focused on performance measurements involving relative rates of drug-maintained responding, discrete-trial choice determinations, and response cost or progressive ratio values. Relative rate measures have proved historically difficult to use for reliable reinforcement strength determinations. Discrete-trial choice procedures for assessing the relative reinforcing properties of stimulus events have recently been reported to effectively discriminate between different drugs and different doses of the same drug. Additionally, response cost or progressive ratio procedures involving systematic increases in the number of responses required for successive drug reinforcements have begun to reveal orderly relationships between different reinforcing drugs at various doses and a "breaking point" measure of the relative strength of a reinforcer. Comparisons between selected doses of cocaine, methylphenidate, and secobarbital with a series of five baboons using this procedure have shown that over the same behaviorally active dose range, cocaine breaking points were higher than all of the breaking points obtained with methylphenidate. Dose-response differences were also revealed in "breaking point" comparisons between secobarbital on the one hand, and methylphenidate and cocaine, on the other.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 821784

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  14 in total

1.  Progressive-ratio performance in the rhesus monkey maintained by opiate infusions.

Authors:  F Hoffmeister
Journal:  Psychopharmacology (Berl)       Date:  1979-04-11       Impact factor: 4.530

2.  Social influences on morphine sensitization in adolescent females.

Authors:  Rebecca S Hofford; Kris W Roberts; Paul J Wellman; Shoshana Eitan
Journal:  Drug Alcohol Depend       Date:  2010-04-24       Impact factor: 4.492

Review 3.  William L. Woolverton: a case history in unraveling the behavioral pharmacology of stimulants.

Authors:  Michael A Nader; Robert L Balster; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2014-05-20       Impact factor: 5.250

Review 4.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

5.  Progressive-ratio performance maintained by drug infusions: comparison of cocaine, diethylpropion, chlorphentermine, and fenfluramine.

Authors:  R R Griffiths; J V Brady; J D Snell
Journal:  Psychopharmacology (Berl)       Date:  1978-01-31       Impact factor: 4.530

Review 6.  Optogenetics: potentials for addiction research.

Authors:  Zhen Fang Huang Cao; Denis Burdakov; Zoltán Sarnyai
Journal:  Addict Biol       Date:  2011-10       Impact factor: 4.280

7.  Comparison of behavior maintained by infusions of eight phenylethylamines in baboons.

Authors:  R R Griffiths; G Winger; J V Brady; J D Snell
Journal:  Psychopharmacology (Berl)       Date:  1976-11-24       Impact factor: 4.530

8.  Cocaine abuse versus cocaine dependence: cocaine self-administration and pharmacodynamic response in the human laboratory.

Authors:  Sharon L Walsh; Eric C Donny; Paul A Nuzzo; Annie Umbricht; George E Bigelow
Journal:  Drug Alcohol Depend       Date:  2009-08-29       Impact factor: 4.492

9.  Lobeline attenuates progressive ratio breakpoint scores for intracranial self-stimulation in rats.

Authors:  Paul J Wellman; Audrea E Elliott; Stephanie Barbee; Chelsie N Hollas; P Shane Clifford; Jack R Nation
Journal:  Physiol Behav       Date:  2007-12-31

10.  Characterization of methylphenidate self-administration and reinstatement in the rat.

Authors:  Leigh C P Botly; Christie L Burton; Zoë Rizos; Paul J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2008-05-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.